Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 18/20 | 0.42 |
| ▸ | PDE3A | Q14432 | 18/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 5/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.41 |
| ▸ | PDE4A | P27815 | 3/20 | 0.34 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.34 |
| ▸ | PDE3B | Q13370 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3126420 | 0.88 | PDE4B (0.44) | PDE4BPDE3APDE4DSLC6A2PDE4A | |
| SCHEMBL3344105 | 0.87 | PDE4B (0.44) | PDE4BPDE3APDE4DSLC6A2PDE4A | |
| SCHEMBL3241318 | 0.83 | PDE4B (0.59) | PDE4BPDE3APDE4DPDE4APDE4C | |
| SCHEMBL3114417 | 0.83 | PDE4D (0.41) | PDE4BPDE3APDE4DSLC6A2PDE4A | |
| SCHEMBL2845710 | 0.78 | PDE4B (0.41) | PDE4BPDE3APDE4DSLC6A2PDE4A | |
| SCHEMBL3128095 | 0.76 | PDE4B (0.61) | PDE4BPDE3APDE4DSLC6A2 | |
| SCHEMBL3126335 | 0.76 | PDE4B (0.61) | PDE4BPDE3APDE4DSLC6A2 | |
| SCHEMBL3111847 | 0.75 | PDE4B (0.70) | PDE4BPDE3APDE4DPDE4APDE4C | |
| SCHEMBL3119075 | 0.75 | PDE4B (0.62) | PDE4BPDE3APDE4DSLC6A2 | |
| SCHEMBL3119047 | 0.73 | PDE4B (0.42) | PDE4BPDE3APDE4DPDE4APDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100160335-A1 | PYRIDAZINONE DERIVATIVE AND PDE INHIBITOR CONTAINING THE SAME AS ACTIVE INGREDIENT | KYORIN PHARMACEUTICAL CO., LTD. | 2010-06-24 | — | — | US | disclosed |
| US-20100160335-A1 | PYRIDAZINONE DERIVATIVE AND PDE INHIBITOR CONTAINING THE SAME AS ACTIVE INGREDIENT | KYORIN PHARMACEUTICAL CO., LTD. | 2010-06-24 | — | — | US | disclosed |
| US-20100160335-A1 | PYRIDAZINONE DERIVATIVE AND PDE INHIBITOR CONTAINING THE SAME AS ACTIVE INGREDIENT | KYORIN PHARMACEUTICAL CO., LTD. | 2010-06-24 | — | — | US | disclosed |
| EP-2168959-A1 | PYRIDAZINONE DERIVATIVE AND PDE INHIBITOR CONTAINING THE SAME AS ACTIVE INGREDIENT | Kyorin Pharmaceutical Co., Ltd. (JP) | 2010-03-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160335-A1 | PYRIDAZINONE DERIVATIVE AND PDE INHIBITOR CONTAINING THE SAME AS ACTIVE INGREDIENT | PDE3A, PDE5A, PDE2A | PDE4B 8/4885PDE3A 1/4885PDE4D 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.